A phase I clinical trial of stereotactic body radiotherapy for patients with cervical cancer unsuitable for intracavitary brachytherapy

A phase I clinical trial of stereotactic body radiotherapy for patients with cervical cancer unsuitable for intracavitary brachytherapy - A phase I clinical trial of stereotactic body radiotherapy for patients with cervical cancer unsuitable for intracavitary brachytherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020519

Enrollment

Registered

2016-01-11

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Whole pelvic irradiation using IMRT: 45 Gy/25 fr. SBRT for primary lesion: 19.5 - 22.5 Gy/3 fr.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. pathological diagnosis of primary cervical cancer 2. FIGO stage; Ib1-IIIB 3. N stage 0-1, Clinical stage Ib1-IIIb 4. Unsuitable for intracavitary brachytherapy 5. Age; 20- 6. ECOG PS; 0-2 7. No previous radiotherapy in the pelvic organs 8. Written informed consent 9. Adequate organ function

Exclusion criteria

Exclusion criteria: 1. Serious medical or psychological problems 2. Other active cancer 3. Be pregnant or just after giving birth

Design outcomes

Primary

Measure	Time frame
Decision of the recommended dose by adverse effects in 6 months after the treatment	—

Secondary

Measure	Time frame
Response rate in the arm of recommend dose Local control Adverse events	—

Countries

Japan

Contacts

Public ContactKei Ito

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Radiation Oncology

keiito@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026